Novartis AG (NOVN.SW)

91,82 -0,89 (-0,96%) Ab 05:12PM CEST. Markt geöffnet.

Novartis AG

Lichtstrasse 35
Basel 4056
Switzerland
41 61 324 1111
https://www.novartis.com

Sektor(en): Healthcare
Branche: Drug Manufacturers—General
Vollzeitmitarbeiter: 103.000

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Vasant Narasimhan	Chief Exec. Officer	5,14M	N/A	1976
Mr. Harry Kirsch	Chief Financial Officer	2,61M	N/A	1965
Dr. Klaus Moosmayer Ph.D.	Chief Ethics, Risk & Compliance Officer	1,42M	N/A	1968
Ms. Karen L. Hale	Chief Legal Officer	2,14M	N/A	1968
Dr. Robert Kowalski Pharm.D.	Chief People & Organization Officer	1,92M	N/A	1968
Dr. Steffen Lang Ph.D.	Pres of Operations	2,14M	N/A	1967
Mr. Victor Bulto	Pres of Innovative Medicines US	2,39M	N/A	N/A
Dr. Shreeram Aradhye M.D.	Pres of Global Drug Devel. & Chief Medical Officer	2,09M	N/A	1963
Mr. Aharon Gal Ph.D.	Chief Strategy & Growth Officer	5,75M	N/A	N/A
Mr. Richard Saynor	Chief Exec. Officer of Sandoz	2,41M	N/A	1967

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in CHF.

Beschreibung

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Corporate Governance

Novartis AGs ISS Governance QualityScore, Stand 1. September 2023, lautet 1. Die grundlegenden Scores sind Audit: 1, Vorstand: 2, Shareholderrechte: 1, Kompensation: 1.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.